AstraZeneca (AZN) Given a GBX 4,080 Price Target by Goldman Sachs Group Analysts

AstraZeneca (LON:AZN) has been assigned a GBX 4,080 ($53.31) price target by stock analysts at Goldman Sachs Group in a report issued on Thursday. The brokerage presently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group’s price target would indicate a potential downside of 33.90% from the company’s previous close.

Several other analysts also recently weighed in on the company. UBS Group set a GBX 5,900 ($77.09) price objective on AstraZeneca and gave the company a “neutral” rating in a report on Thursday. Bryan, Garnier & Co downgraded AstraZeneca to a “neutral” rating in a report on Thursday. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a report on Thursday. Shore Capital restated a “hold” rating on shares of AstraZeneca in a report on Tuesday. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 30th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 5,831.89 ($76.20).

AZN stock opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Why do companies engage in swaps?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply